NYSE · Shell Companies · USD

Jackson Acquisition Company II (JACS) Stock Analysis

Jackson Acquisition Company II (JACS) is a Shell Companies stock listed on NYSE and quoted in US Dollar.

JACS

$10.72

−$0.02 (−0.19%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JACS with… →

JACS Key Statistics

As of Sep 4, 2026

Trading

Open: $10.72
Previous Close: $10.74
52-Week Range: 10.33–10.75
Volume: 8.10K

Valuation

Market Cap: $317.20M
P/E Ratio: 36.97
EPS (ttm): 0.29

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): $9.12M
Profit margin: 0.00%
Shares Outstanding: 23.84M
1-Year Return: +3.57%

Dividend and dates

Avg Volume: 31.23K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

JACS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+2.88%
2025	+4.62%

As of September 4, 2026.

JACS Valuation vs Shell Companies Median

Median of 587 stocks

Metric	JACS	Shell Companies median	vs median
P/E	36.97	45.20	18% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 587 Shell Companies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Jackson Acquisition Company II (JACS) at $317.20M. The company sits in the Financial Services sector, in the Shell Companies industry.

The most recent close on file for JACS is $10.72, dated September 4, 2026. That is −$0.02 (−0.19%) against the previous close. Over the past 52 weeks the price has ranged from $10.33 to $10.75. The latest close sits 3.78% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Net income for the same year was $9.12M. Profit margin runs at 0%. Earnings per share on a trailing basis come to 0.29.

Valuation Assessment

JACS trades at a trailing price-to-earnings ratio of 36.97. That is 18.21% below the Shell Companies median of 45.2. The medians here are taken across 587 Shell Companies companies that report the metric.

Daily returns over the trailing 1 year annualize to a volatility of 2.76%. The trailing one-year price return is +3.57%. The stored price history starts on January 30, 2025, and the total return since then is +7.63%.

Growth & Income

No dividend is on file for JACS.

2026 is still running; the price is +2.88% year to date. The record holds one complete calendar year, 2025, which returned +4.62%.

Peer Comparison

Jackson Acquisition Company II (JACS) operates in the Shell Companies industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Jackson Acquisition Company II	JACS	$317.20M	37.0
Churchill Capital Corp XI	CCXI	$746.38M	—
Churchill Capital Corp X	CCCX	$711.00M	—
Drugs Made In America Acquisition II Corp.	DMII	$647.83M	35.1

The Shell Companies industry average P/E ratio is 45.2x. Jackson Acquisition Company II trades at a P/E of 37.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Shell Companies Stocks

CCXI

Churchill Capital Corp XI

$746.38M

CCCX

Churchill Capital Corp X

$711.00M

DMII

Drugs Made In America Acquisition II Corp.

$647.83M

BCSS

Bain Capital GSS Investment Corp.

$602.40M

EVAC

EQV Ventures Acquisition Corp. II

$602.01M

CXII

Churchill Capital Corp XII

$594.94M

View all Shell Companies stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.08T

JPM

JPMorgan Chase & Co.

$953.33B

Visa Inc.

$700.27B

Mastercard Incorporated

$507.39B

BAC

Bank of America Corporation

$438.31B

View all Financial Services stocks →

About Jackson Acquisition Company II

Jackson Acquisition Company II does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2024 and is based in Alpharetta, Georgia.

Visit website →